Journal ArticleOPEN ACCESS

Drugging RB1 deficiency: Synthetic lethality with aurora kinases

Cancer Discovery (2019) 9(2) 169-172
DOI: 10.1158/2159-8290.CD-18-1448
8Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Two recent reports describe pharmacologic approaches to specifically treat RB1 -mutant cancers. The basis of this approach is a synthetic lethal relationship between RB1 mutations and inhibition of Aurora kinases A or B.

Cite

CITATION STYLE

APA

Dick, F. A., & Li, S. S. C. (2019). Drugging RB1 deficiency: Synthetic lethality with aurora kinases. Cancer Discovery, 9(2), 169–172. https://doi.org/10.1158/2159-8290.CD-18-1448

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free